{"id":441857,"date":"2021-02-23T08:33:16","date_gmt":"2021-02-23T13:33:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441857"},"modified":"2021-02-23T08:33:16","modified_gmt":"2021-02-23T13:33:16","slug":"albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/","title":{"rendered":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the <em>New Drug Launches Panel<\/em> on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2.<\/p>\n<p>The Company will also be participating in the H.C. Wainwright Global Life Sciences Conference March\u00a09-10, 2021. Simon Harford, Chief Financial Officer, and Pamela Stephenson, Chief Commercial Officer, will take part in a fireside chat on March 9 at 7am ET, which will be available on-demand on the Albireo Media &amp; Investors page <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lP2tsvsdrYD08tsDgmI7LNbJ1vuKU2uGQ9QEU0rmuC8cR0FHllUsmTz348LW0N6EWg0UHaz0xsHheK5_HxhZ8iEZNhDxMojtAH1qg_px2aE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir.albireopharma.com<\/a>. Ron Cooper and members of the management team will also host meetings with investors on March 9.<\/p>\n<p>\n        <strong>About Albireo<\/strong><br \/>\n        <br \/>Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo\u2019s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca\u00a0in 2008 and is headquartered in\u00a0Boston, Massachusetts, with its key operating subsidiary in\u00a0Gothenburg, Sweden. The\u00a0<em>Boston Business Journal<\/em>\u00a0named Albireo one of the 2020 Best Places to Work in\u00a0Massachusetts for the second consecutive year. For more information on Albireo, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n-KcGswSnhRfou4iV_0Pb8FVpXJcLraescI97jZuKzvC92VTXerMvYwFgHj_NQVajzLNi8VTBzRfQtRxG-prvqX8dTGsV3Ni_DPGwJgIRDp6Yg4uKkCMoOqobx5Mf-4TTbOi8hX8DaK0HhnOR5j_THTRNRNgHsUsv1Dk8QJz2eriFAxcfSSb8MkpaPDjFNJ7Eg21NpSXcUOHBwaSEUK8rlmDS_9NrMlxB3gVUtQG_LgXRE_yixCurB6DbTvbHuJjg3XLyuoksuX5FYe11ykUYw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.albireopharma.com<\/a>.<\/p>\n<p>\n        <strong>Media &amp; Investor Contacts:<\/strong><br \/>\n        <br \/>Colleen Alabiso, 857-356-3905,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1EB4sU1cCfCkB_5NmMunxDnK6Cs_uRb7t9nw-jTZSG4oXt1QjXiuhwoc0RHG_idh3DqbExKqBpphGE24XRhezeg3NXo8sQGjEKedV0P3IheSUnXZpeda4G2igfhcBy_a\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">colleen.alabiso@albireopharma.com<\/a><br \/>Hans Vitzthum,\u00a0LifeSci Advisors, LLC., 617-430-7578<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8abfd6c3-ea83-47ec-9260-7a80ebf44ee5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2. The Company will also be participating in the H.C. Wainwright Global Life Sciences Conference March\u00a09-10, 2021. Simon Harford, Chief Financial Officer, and Pamela Stephenson, Chief Commercial Officer, will take part in a fireside chat on March 9 at 7am ET, which &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441857","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2. The Company will also be participating in the H.C. Wainwright Global Life Sciences Conference March\u00a09-10, 2021. Simon Harford, Chief Financial Officer, and Pamela Stephenson, Chief Commercial Officer, will take part in a fireside chat on March 9 at 7am ET, which &hellip; Continue reading &quot;Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T13:33:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences\",\"datePublished\":\"2021-02-23T13:33:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/\"},\"wordCount\":298,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/\",\"name\":\"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\",\"datePublished\":\"2021-02-23T13:33:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk","og_description":"BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2. The Company will also be participating in the H.C. Wainwright Global Life Sciences Conference March\u00a09-10, 2021. Simon Harford, Chief Financial Officer, and Pamela Stephenson, Chief Commercial Officer, will take part in a fireside chat on March 9 at 7am ET, which &hellip; Continue reading \"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T13:33:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences","datePublished":"2021-02-23T13:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/"},"wordCount":298,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/","name":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=","datePublished":"2021-02-23T13:33:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzYwMiMzOTg5NDU3IzIwODA2NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/albireo-to-participate-in-cowen-and-h-c-wainwright-global-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441857"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441857\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}